Investors reacted negatively to the news. The company’s stock fell more than 16% yesterday. It’s also a setback in ...

Chris Viehbacher's efforts to reinvigorate Biogen are continuing to take shape ... as chief executive of gene therapy start-up Voyager Therapeutics. She has had a long career in biopharma ...

Biogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Alzheimer’s in a collaboration worth more than $2.7 billion.